Health Catalyst (HCAT) closed at $1.44 on November 10, 2026, down 4.6% from the previous close, on volume of 395,162 shares (30-day average 370,215).
Data as of November 10, 2026.
TipRanks (Mon, 9-Nov 6:30 AM ET)
William Blair Remains a Buy on Health Catalyst (HCAT)
TipRanks (Fri, 6-Nov 6:55 PM ET)
Health Catalyst GAAP EPS of $0.53 beats by $0.74, revenue of $56.2M beats by $0.82M
Seeking Alpha News (Thu, 5-Nov 4:15 PM ET)
Health Catalyst Reports Third Quarter 2026 Results
Globe Newswire (Thu, 5-Nov 4:03 PM ET)
Globe Newswire (Thu, 22-Oct 4:05 PM ET)
Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Mon, 14-Sep 6:32 PM ET)
Health Catalyst Strengthens Its Board with the Appointment of Tami Reller
PRNewswire (Mon, 14-Sep 4:20 PM ET)
Health Catalyst Appoints Simeon Kohl as Chief Executive Officer and President
Globe Newswire (Tue, 8-Sep 8:00 AM ET)
Health Catalyst to Participate in Upcoming Investor Conference
Globe Newswire (Mon, 31-Aug 4:05 PM ET)
Health Catalyst’s $147 Million Vitalware Sale Sharpens AI Focus and Strengthens Balance Sheet
Market Chameleon (Thu, 4-Jun 5:52 AM ET)
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platform, analytics applications and support services and generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Health Catalyst trades on the NASDAQ stock market under the symbol HCAT.
As of November 10, 2026, HCAT stock price declined to $1.44 with 395,162 million shares trading.
HCAT has a beta of 1.79, meaning it tends to be more sensitive to market movements. HCAT has a correlation of 0.06 to the broad based SPY ETF.
HCAT has a market cap of $108.37 million. This is considered a Micro Cap stock.
Last quarter Health Catalyst reported $56 million in Revenue and -$.03 earnings per share. This beat revenue expectation by $940,520 and exceeded earnings estimates by $.02.
In the last 3 years, HCAT traded as high as $11.41 and as low as $.96.
The top ETF exchange traded funds that HCAT belongs to (by Net Assets): VTI, VXF, FESM, SCHA, IWC.
HCAT has underperformed the market in the last year with a price return of -49.1% while the SPY ETF gained +12.9%. HCAT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.8% and -11.7%, respectively, while the SPY returned -2.8% and -2.0%, respectively.
HCAT support price is $1.43 and resistance is $1.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HCAT shares will trade within this expected range on the day.